Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Rhea-AI Summary
Alterity Therapeutics (NASDAQ: ATHE) received positive FDA feedback after a second Type C meeting on its planned ATH434 Phase 3 program in Multiple System Atrophy (MSA). The FDA provided written support for the program's chemistry, manufacturing, and control (CMC) elements, and manufacturing scale-up is progressing.
An End-of-Phase 2 meeting remains on track for mid-2026, moving the company closer to Phase 3 initiation while clinical pharmacology and non-clinical topics were addressed in an earlier Type C meeting.
Positive
- FDA provided written alignment on CMC elements
- Manufacturing scale-up is progressing in parallel
- End-of-Phase 2 meeting remains on track for mid-2026
Negative
- No FDA approval — Phase 3 initiation remains planned, not completed
- Program readiness depends on final End-of-Phase 2 outcomes mid-2026
News Market Reaction – ATHE
In the Apr 27 session, ATHE gained 4.76%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.6% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Phase 2 data analysis | Positive | -5.7% | New Phase 2 analyses showing slowed functional decline versus placebo on key scales. |
| Mar 30 | FDA Type C feedback | Positive | +13.0% | Positive FDA Type C feedback on clinical pharmacology and non-clinical development plans. |
| Oct 09 | Phase 2 data presentation | Positive | +4.4% | Phase 2 ATH434-201 data with efficacy and biomarker signals in MSA at MDS Congress. |
| Sep 15 | Phase 2 trial update | Positive | -5.0% | Promising Phase 2 clinical trial data showing disease modification and target engagement. |
| Jul 28 | Open-label Phase 2 topline | Positive | -14.8% | Open-label Phase 2 topline data showing reduced disease progression versus historical controls. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical and regulatory ATH434 updates have produced mixed reactions, with both strong rallies and notable selloffs on positive data over the last 5 clinical-trial-tagged events.
Over the past several months, Alterity has repeatedly reported positive clinical and regulatory milestones for ATH434 in Multiple System Atrophy. Phase 2 data, including efficacy and biomarker signals, were presented across major neurology conferences from July 2025 onward. A March 30, 2026 FDA Type C meeting yielded supportive feedback on clinical pharmacology and non-clinical plans. Despite this, share reactions to similar clinical updates have varied, with both double-digit gains and declines around these announcements.
Key Terms
u.s. food and drug administration (fda) regulatory
multiple system atrophy (msa) medical
chemistry, manufacturing, and control (cmc) technical
phase 3 medical
end-of-phase 2 meeting regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
| – Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – |
| – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale-up progressing in parallel – |
| – End-of-Phase 2 meeting with FDA remains on track for mid-2026 – |
MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). MSA is a rare, rapidly progressive neurodegenerative disease with no approved disease-modifying treatments.
This second Type C Meeting builds on Alterity’s recent regulatory interactions with the FDA and represents a further step towards readiness for the planned Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans related to the chemistry, manufacturing, and control (CMC) elements of the program. The first Type C Meeting, which was announced in March, related to clinical pharmacology and non-clinical development aspects of the program.
“Confirming alignment with the FDA on the chemistry and manufacturing of ATH434 represents another critical step toward initiation of our Phase 3 program,” said David Stamler, M.D., Chief Executive Officer of Alterity. “The FDA endorsed our plans related to the manufacture and testing of ATH434 for use in our Phase 3 trial and ultimately for commercialization, if approved. We continue to advance ATH434 through the necessary steps to initiate our pivotal development program, and we look forward to finalizing our plans with the FDA at an End-of-Phase 2 meeting that remains on track for mid-year 2026.”
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.
Authorisation & Additional information
This announcement was authorized by the Board of Directors of Alterity Therapeutics Limited.
Contacts:
Investors:
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
